Daver, N. G., Montesinos, P., DeAngelo, D. J., Wang, E. S., Todisco, E., Tarella, C., … Zweidler-McKay, P. A. (2020). A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Daver, Naval Guastad, Pau Montesinos, Daniel J. DeAngelo, Eunice S. Wang, Elisabetta Todisco, Corrado Tarella, Giovanni Martinelli, et al. “A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Todisco E, Tarella C, et al. A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Daver, Naval Guastad, et al. “A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Daver NG, Montesinos P, DeAngelo DJ, Wang ES, Todisco E, Tarella C, Martinelli G, Erba HP, Deconinck E, Sweet KL, Walter RB, Levy MY, Pemmaraju N, Lane AA, Rizzieri D, Konopleva M, Sloss CM, Wang J, Malcolm KE, Zweidler-McKay PA. A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. JOURNAL OF CLINICAL ONCOLOGY. 2020.